drugset / Trial / NCT06571422
Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors
Phase 1
Active not recruiting
59 enrolled
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is an open-label, dose-escalation and expansion, Phase I clinical study to evaluate the safety, tolerability, PK characteristics and preliminary antitumor activity of WJ47156 monotherapy and in combination with toripalimab in patients with advanced malignant solid tumors. The study consists of two parts, including monotherapy (Part 1) and combination therapy (Part 2).
Timeline
- Start
- 2024-10-23
- Primary completion
- 2026-12-15
- Completion
- 2027-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | JS207 | Monoclonal antibody | — | Intravenous |
| Subject | Toripalimab | Monoclonal antibody | — | Intravenous |
| Subject | WJ47156 | Unknown | — | — |